CLEC10A and cancer: Additional to higher serum HERV-K mRNA levels and serum anti-HERV-K antibody titers in women with ductal carcinoma in situ and stage I disease compared to women without cancer, Wang-Johanning et al. (2014) reported that elevated HERV-K (HML-2) antibodies and mRNA levels in the blood can be an early indicator of future metastatic disease development [72].